InvestorsHub Logo
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Friday, 06/24/2022 10:26:14 PM

Friday, June 24, 2022 10:26:14 PM

Post# of 1162
FDA approves BMY’s Breyanzi for second-line LBCL:

https://www.businesswire.com/news/home/20220427005982/en

The approval is based on phase-3 data reported one year ago, in which Breyanzi showed statsig-superior EFS compared to SoC (#msg-164317285).

Breyanzi will compete in this newly approved indication with GILD’s Yescarta (#msg-167110232).

Breyanzi was initially FDA-approved for third-line LBCL in Feb 2021 (#msg-161552697). This is the drug at the heart of the lawsuit by former CELG shareholders (#msg-169238809).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News